The trial’s primary efficacy goal is to measure the rate of growth of atrophic lesions in the retina. Credit: SaiArLawKa2 / Shutterstock.com. Belite Bio has concluded the final participant visit in ...

Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of ...

Revolution will now explore daraxonrasib’s potential as a monotherapy and in combination with chemotherapy in late-stage PDAC trials.

Karyopharm Therapeutics has reached a significant milestone by completing patient enrolment for its Phase III SENTRY trial.

The editorial team covers all the latest drug and medical device news from this year’s ESC Congress. JuShoot via Shutterstock.com. Eyes in the pharma and medtech industries are directed to the ...

Maia Biotechnology’s telomerase modifier, ateganosine (THIO) demonstrated efficacy when given before Regeneron’s immune checkpoint inhibitor Libtayo (cemiplimab) during a Phase II trial in non-small ...

In August, Regeneron announced positive results from Phase III clinical trial NIMBLE evaluating the efficacy and safety of ...

PhaseV has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials using advanced ...

These readouts will help Regeneron structure the confirmatory trials for the two allergy combination therapies.

Paul Hingst, Prasun Mishra, and Naymisha Patel discussed risk management in clinical trials as a key measure to ensure supply and trial success. Credit: Athanasios Psimadis/ Arena International Events ...

Ascletis Pharma’s subcutaneous glucagon-like peptide 1 receptor agonist (GLP-1RA) ASC30 has demonstrated a half-life of 75 days when used as a maintenance therapy for obesity in a Phase Ib trial.